Napabucasin was discovered and originally identified to be a cancer stemness inhibitor by suppressing the signal transducer and activator of transcription 3 (STAT3) [7], whose phosphorylation till pSTAT3 triggers the transcription of genes implicated in promoting tumor growth and survival and in regulating inflammation in the tumor microenvironment. This evidence concerns the gene STAT3 and cancer.